multitargeted antifolate pemetrexed alimta (Eli Lilly)
Structured Review
Multitargeted Antifolate Pemetrexed Alimta, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multitarget+antifolate/antifolate+pemetrexed+alimta/pm12094334-6-4-5
Average 90 stars, based on 1 article reviews
Images
Related Articles
other:Article Title: First assessment of whole-brain radiation therapy combined with pemetrexed-based chemotherapy in non-small-cell lung carcinoma Article Snippet: The folate antimetabolite pemetrexed was approved for the treatment of patients with metastatic nonsquamous non-small-cell lung carcinoma.. Its activity on brain metastases makes pemetrexed attractive in combination with whole-brain radiation therapy (WBRT), but it could also potentially increase toxicity.. We examined the medical records of 43 consecutive patients with brain metastases from non-small-cell lung carcinoma. Article Title: Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer Article Snippet: Article Title: SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolate. Article Snippet: However, recently a protocol was developed that describes the combined application of an Activity Assay:Article Title: Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC). Article Snippet: Standard therapy for advanced or metastatic non-small cell lung cancer (NSCLC) has primarily consisted of traditional cytotoxic chemotherapy, although use of targeted therapies has been approved in specific settings.. Antiangiogenic agents represent a promising therapeutic strategy for treatment of advanced NSCLC.. Bevacizumab is currently approved when given in combination with firstline platinum-based therapy in selected patients with nonsquamous NSCLC. Article Title: Personalized medicine for non-small-cell lung cancer: implications of recent advances in tissue acquisition for molecular and histologic testing. Article Snippet: In light of recent advances in individualized therapy for non–small-cell lung cancer (NSCLC), molecular and histologic profiling is essential for guiding therapeutic decisions.. Results of these analyses may have implications for both response (eg, molecular testing for EGFR [epidermal growth factor receptor] mutations) and safety (eg, contraindications for squamous histology) in NSCLC.. Most patients with NSCLC present with unresectable advanced disease; therefore, greater emphasis is being placed on minimally invasive tissue acquisition techniques, such as small biopsy and cytology specimens. Mutagenesis:Article Title: Personalized medicine for non-small-cell lung cancer: implications of recent advances in tissue acquisition for molecular and histologic testing. Article Snippet: In light of recent advances in individualized therapy for non–small-cell lung cancer (NSCLC), molecular and histologic profiling is essential for guiding therapeutic decisions.. Results of these analyses may have implications for both response (eg, molecular testing for EGFR [epidermal growth factor receptor] mutations) and safety (eg, contraindications for squamous histology) in NSCLC.. Most patients with NSCLC present with unresectable advanced disease; therefore, greater emphasis is being placed on minimally invasive tissue acquisition techniques, such as small biopsy and cytology specimens. Injection:Article Title: In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates. Article Snippet: The overexpression of the folate receptor (FR) in a variety of malignant tumors, along with its limited expression in healthy tissues, makes it an attractive tumor-specific molecular target.. Noninvasive imaging of FR using radiolabeled folate derivatives is therefore highly desirable.. Given the advantages of positron emission tomography (PET) and the convenience of Ga production, the aim of our study was to develop a new Ga-folate-based radiotracer for clinical application. |
